CNSP
CNS Pharmaceuticals, Inc.Price
Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.
- R May 4 CNS Pharmaceuticals entered into a securities purchase agreement for…
- B May 18 2 insiders buy $44.0K at $4.84
- R May 19 CNS Pharmaceuticals filed a resale S-3 registering up to 9,793,479 s…
- R May 27 CNS Pharmaceuticals' S-3 shelf registration (File No. 333-296033) be…
- X Jul 31 Short interest falls 27.9% to 11.4K
- X Aug 31 Short interest falls 82.6% to 2.2K
- X Sep 15 Short interest jumps 35.4% to 3.0K
- X Sep 30 Short interest falls 69.8% to 898
Signal stack
Where each data set points today.
- InsidersBULLISH
2 insiders bought $44.0K at an average $4.84. No open-market sales.
- InstitutionsMIXED
Q2 2026: 1 added (0 new), 0 trimmed or exited.
- TrendDOWNTREND
14% below its 50-day average.
Who's buying
13F· Q2 2026| Fund | Move | Value |
|---|---|---|
| UBS Group AG | DOUBLED | $7.0K |
| UBS Group AG | NEAR_EXIT | $3.2K |
| UBS Group AG | ADD | $26.5K |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
last action Sep 2025Price is below the lowest target. Median implies +116%.Targets as of Oct 27, 2026.
| Date | Firm | Rating |
|---|---|---|
| Sep 12, 2025 | Maxim Group UPGRADE | Buy |
| Mar 25, 2025 | Maxim Group DOWNGRADE | Hold |
Insider ledger
Form 4| Date | Insider | Type | Value |
|---|---|---|---|
| Aug 14, 2026 | Levin Rami CEO and President | EXERCISE | 4,750 sh |
| May 18, 2026 | Fisher Michal Director | BUY | $10.0K |
| May 18, 2026 | Charles Faith L. Director | BUY | $34.0K |
| Mar 2, 2026 | O'Loughlin Steve Chief Financial Officer | AWARD | 9,500 sh |
| Mar 2, 2026 | Faulkner Eric Chief Technology Officer | AWARD | 9,500 sh |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$0.27 | -$0.27–-$0.27 | +63.5% | $0.00 |
| Next Q | -$0.27 | -$0.27–-$0.27 | +64.9% | $0.00 |
| Current FY | -$1.65 | -$1.65–-$1.65 | +55.0% | $0.00 |
| Next FY | -$1.66 | -$1.66–-$1.66 | +42.6% | $0.00 |
Short side
FINRA· Oct 15, 2026SecBot reports
5 filings · 0 bullish · 3 bearish · 2 neutral- NEUTRAL 8-KOct 2, 2026
CNS Pharmaceuticals held its 2026 Annual Meeting on September 30, 2026, where stockholders…
The 650,000 share increase to the equity plan provides headroom for future employee and director equity grants, but no immediate dilution event occurred. Monitor subsequent filings for actual option…
- NEUTRAL 8-KJul 2, 2026
CNS Pharmaceuticals filed an 8-K posting an investor presentation detailing its strategic pivot…
The strategic pivot and $22.5M cash position signal an active asset acquisition search. Traders should monitor for announcements of in-licensed or acquired programs, which could serve as near-term…
- BEARISH EFFECTMay 27, 2026
CNS Pharmaceuticals' S-3 shelf registration (File No. 333-296033) became effective on May 26…
With the shelf now effective, selling shareholders can immediately begin selling into the market. The massive overhang relative to the $8M market cap creates strong downward pressure. Traders should…
- BEARISH S-3May 19, 2026
CNS Pharmaceuticals filed a resale S-3 registering up to 9,793,479 shares (650,000 common +…
Expect significant selling pressure once the S-3 becomes effective. The pre-funded warrants are essentially zero-cost to exercise, so holders will likely dump shares quickly. Monitor daily volume…
All CNSP filing & press-release reports (5)
- 8-K reportOct 2, 2026
- 8-K reportJul 2, 2026
- EFFECT reportMay 27, 2026
- S-3 reportMay 19, 2026
- 8-K reportMay 4, 2026